Evidence map›Paper›PMID 30726546›Full record

SynthesisMolecular diagnosis & therapy2019

Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Madhav Madurantakam Royam, Chellan Kumarasamy, Siddhartha Baxi, Ajay Gupta, Nachimuthu Ramesh, Gothandam Kodiveri Muthukaliannan, Rama Jayaraj

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Molecular diagnosis & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Madhav Madurantakam RoyamDepartment of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.ORCID http://orcid.org/0000-0002-7885-460X
Chellan KumarasamyNorth Terrace Campus, University of Adelaide, Adelaide, SA, Australia.
Siddhartha BaxiGenesis Cancer Care Centre, Bunbury, Western Australia, 6230, Australia.
Ajay GuptaAmerican Oncology Institute, Nagpur, 530019, India.
Nachimuthu RameshDepartment of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
Gothandam Kodiveri MuthukaliannanDepartment of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
Rama JayarajDepartment of Clinical Sciences, College of Health and Human Sciences, Yellow 1.1.05, Charles Darwin University, Ellengowan Drive, Darwin, Northern Territory, 0909, Australia. Rama.Jayaraj@cdu.edu.au.ORCID http://orcid.org/0000-0002-2179-0510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFindings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting.

objectiveWe conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways.

methodsUsing PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran's Q test and the I

resultsOf the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug-regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428-1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%.

conclusionStudies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO REGISTRATION NUMBER: CRD42017082196.

Indexed as

Biomarkers, TumorColorectal NeoplasmsDrug Resistance, NeoplasmFluorouracilHumansMicroRNAsOxaliplatinTheranostic NanomedicineBiomarkers, TumorFluorouracilMicroRNAsOxaliplatin

Identifiers

PMID30726546

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.